this carefully. And I think those attacks are unjustified, when, in fact, the DRB has acted in a very responsible manner.

The rest of this statement is in answer to the questions in your letter. I think the important thing is that the amount of information available needs to be increased to the individual making the selection. In making the decision about the selection, the point is to emphasize the amount of information available. And I think the manufacturing plant is often not known.

For example, when Mylan Laboratories makes a number of different tetracyclines and then Mylan does not appear on the final packed form at any place, that is information the prescriber and dispenser need. So that in making the decision of the drug product selection, the most important thing needed by the physician or the pharmacist, but now lacking is information as to the actual manufacturer of the various drug products.

It seems to me that the reasonable conclusion of this whole affair might best be simply to require the distributors of drug products to designate in writing, on each bottle or package of the drug product being dispensed to the pharmacy, the actual manufacturing laboratory or unit in sufficient detail to inform the pharmacist and physician accurately as to the origin of the material. With this information and the price of the various drug products in hand, and the recommended changes in prescription forms, selection of the best product for the lowest cost should not be difficult.

Thank you, sir.

Mr. GORDON. I would like to summarize your statement and ask if my summary is correct. Is this a fair summary of the situation? The Drug Research Board twice passed unanimously a resolution in essence that the antisubstitution laws in the various States should be repealed or substantially modified, is that correct?

Dr. PITTMAN. No. The second time it was 13 to 1, it was almost unanimous.

The CHAIRMAN. With one abstention?

Dr. PITTMAN. The second time one of the industry-related members voted against it.

Mr. GORDON. This resolution was accepted by the parent National Research Council, National Academy of Sciences, is that correct?

Under extreme pressure from the Pharmaceutical Manufacturers Association and the American Medical Association, the Drug Research Board subsequently reversed itself by adopting an amendment offered by one of the industry members. Is that substantially correct?

Dr. PITTMAN. The Drill amendment would have reversed the intent of the thing. This was not accepted by the Assembly of Life Sciences.

Mr. GORDON. The National Research Council refused to accept the reversal, is that correct?

Dr. PITTMAN. That is correct.

Mr. GORDON. So that there is no change in the NAS/NRC position from the document issued in January 1975?

Dr. PITTMAN. That is correct.

Mr. GORDON. And as I understand it, there is a meeting of the DRB called for the latter part of May to reconsider the resolution?